Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $151.00 at Wedbush

Neurocrine Biosciences (NASDAQ:NBIX) had its price target lifted by Wedbush from $149.00 to $151.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright lowered their target price on Neurocrine Biosciences from $198.00 to $192.00 and set a “buy” rating on the stock in a report on Thursday. UBS Group decreased their price objective on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Wall Street Zen raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Sunday, February 8th. Citigroup increased their target price on Neurocrine Biosciences from $175.00 to $203.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Stifel Nicolaus raised their target price on shares of Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Fifteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $177.56.

Neurocrine Biosciences Price Performance

NBIX stock opened at $123.10 on Thursday. The company’s 50 day simple moving average is $140.77 and its 200-day simple moving average is $140.46. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $160.18. The firm has a market capitalization of $12.27 billion, a PE ratio of 26.42, a P/E/G ratio of 0.64 and a beta of 0.31.

Insider Buying and Selling

In other news, CEO Kyle Gano sold 36,400 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer owned 140,407 shares in the company, valued at approximately $18,632,008.90. This trade represents a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director George J. Morrow sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total value of $2,150,550.00. Following the transaction, the director directly owned 7,068 shares in the company, valued at $1,013,339.16. This trade represents a 67.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 61,966 shares of company stock worth $8,625,166 over the last three months. 4.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NBIX. JPMorgan Chase & Co. increased its stake in Neurocrine Biosciences by 59.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,261,747 shares of the company’s stock worth $535,659,000 after buying an additional 1,590,749 shares during the period. AQR Capital Management LLC boosted its position in Neurocrine Biosciences by 83.7% in the 3rd quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock valued at $388,435,000 after buying an additional 1,263,633 shares during the last quarter. Norges Bank acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at about $162,664,000. Los Angeles Capital Management LLC increased its position in shares of Neurocrine Biosciences by 19,454.9% during the second quarter. Los Angeles Capital Management LLC now owns 744,650 shares of the company’s stock worth $93,595,000 after acquiring an additional 740,842 shares during the last quarter. Finally, UBS Group AG increased its position in shares of Neurocrine Biosciences by 169.8% during the fourth quarter. UBS Group AG now owns 983,528 shares of the company’s stock worth $139,494,000 after acquiring an additional 618,956 shares during the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Analysts continue to show conviction in the long‑term story — several firms reiterated Buy/Outperform ratings and high price targets, signaling confidence in the Ingrezza franchise and pipeline potential. TipRanks: Bank of America reiterates Buy
• Positive Sentiment: Recent analyst upgrades/raises include Citigroup lifting its price target (to $204) and Wedbush nudging its target higher — evidence that some investors still see significant upside. Benzinga: Citi/Wedbush price target moves
• Positive Sentiment: Underlying commercial results were strong: full‑year 2025 net product sales and year‑over‑year revenue growth reinforce that Ingrezza remains a durable cash generator. PR Newswire: Q4 and FY2025 results
• Neutral Sentiment: Revenue came in roughly in line with expectations (~$805M), so top‑line growth isn’t the main driver of the decline — the market is reacting to profit/guidance details. MarketBeat: Earnings report & transcript
• Neutral Sentiment: Analyst reactions are mixed: several firms trimmed price targets modestly (RBC, BMO, Needham adjustments) while most maintained Buy/Outperform ratings — creates volatility but not a broad sell consensus. TipRanks: Mixed PT adjustments
• Negative Sentiment: EPS missed expectations — adjusted EPS reported below consensus — which, combined with cautious near‑term commentary, triggered selling pressure. MarketBeat: EPS miss details
• Negative Sentiment: Market commentary flagged “disappointing Ingrezza guidance” as a key catalyst for the decline — investors appear to have expected a stronger 2026 sales outlook. Benzinga: Analysts on Ingrezza guidance
• Negative Sentiment: Trading showed heavy volume and reports noted insider selling activity — both amplify downside momentum in the near term. QuiverQuant: Stock falls, insider selling

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.